Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks
In testimony prepared for a congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.